Idogen AB (OSTO:IDOGEN) Ending Cash Position: kr2.97 Mil (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IDOGEN Idogen AB OSTO:IDOGEN
21 GF Score
Price kr0.12
View Full Analysis

What is Idogen AB Ending Cash Position?

Idogen AB OSTO:IDOGEN 21 Ending Cash Position is kr2.97 Mil as of Mar. 2023. GuruFocus rates OSTO:IDOGEN with a GF Score™ of 21/100.

Idogen AB's Ending Cash Position for the quarter that ended in Mar. 2023 was kr2.97 Mil.

Idogen AB's quarterly Ending Cash Position declined from Sep. 2022 (kr16.74 Mil) to Dec. 2022 (kr5.30 Mil) and declined from Dec. 2022 (kr5.30 Mil) to Mar. 2023 (kr2.97 Mil).

Idogen AB's annual Ending Cash Position declined from Dec. 2020 (kr47.04 Mil) to Dec. 2021 (kr15.56 Mil) and declined from Dec. 2021 (kr15.56 Mil) to Dec. 2022 (kr5.30 Mil).

Idogen AB Ending Cash Position Related Terms

Idogen AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Idogen AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idogen AB Ending Cash Position Chart

Idogen AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 61.61 26.01 47.04 15.56 5.30

Idogen AB Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.63 26.94 16.74 5.30 2.97
OSTO:IDOGEN
21GF Score
Idogen AB OSTO:IDOGEN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idogen AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Idogen AB's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=15.561+-10.257
=5.30

Idogen AB's Ending Cash Position for the quarter that ended in Mar. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.305+-2.332
=2.97

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr2.97 Mil mean?
Idogen AB (OSTO:IDOGEN) has a Ending Cash Position of kr2.97 Mil as of Mar. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Idogen AB and its competitors.
Is Idogen AB's Ending Cash Position too high?
Idogen AB's current Ending Cash Position is kr2.97 Mil. Overall, Idogen AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Idogen AB's Ending Cash Position compare to REGN and VRTX?
Idogen AB's Ending Cash Position of kr2.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Idogen AB and its competitors. Idogen AB's current Ending Cash Position is kr2.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idogen AB stock overvalued right now?
Idogen AB (OSTO:IDOGEN) has a current Ending Cash Position of kr2.97 Mil. The current Ending Cash Position is kr2.97 Mil. Idogen AB's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Idogen AB (OSTO:IDOGEN), the current Ending Cash Position is kr2.97 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Idogen AB Business Description

Address Medicon Village, Scheelevagen 2, Lund, SWE, 223 81
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
21GF Score

Get the complete analysis for OSTO:IDOGEN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price